In the realm of clinical research, obtaining patient consent for trials is a critical step that ensures participants are well-informed and willingly engage in the study.
Exonate‘s flagship product, EXN407, is a topical SRPK1 inhibitor that has shown promising results in both safety and effectiveness as a monotherapy for conditions like diabetic retinopathy and diabetic macular oedema.
programmed cell death protein 1 (PD-1) inhibitor carrelizumab and Rivoceranib in combination (hereinafter referred to as "Double Ai" combination) received a Complete Response Letter (CRL) from the FDA.
On April 23, global biopharmaceutical company Incyte announced the finalization of an agreement to fully acquire clinical-stage drug development company Escient Pharmaceuticals.
This collaboration aims to advance the Phase I/II clinical trials of TG4050, a personalized therapeutic vaccine for patients afflicted with head and neck cancers.
May 18th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.